This filing provides a recast historical baseline for New BD post-separation. The unchanged FY2026 guidance and the Q1 adjusted EPS decline of ~10% YoY warrant monitoring the next quarterly report for revenue and margin trajectory under the new segment structure.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 6 $155.23entry
- T+1 · 7mo ago −0.17%α −0.23% · $154.96
- T+5 · 7mo ago +0.13%α −4.00% · $155.43
- T+20 · 7mo ago −5.85%α −14.83% · $146.15
- T+60 · 5mo ago −1.50%α −14.68% · $152.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BD filed recast historical financial information reflecting the spin-off of its Biosciences and Diagnostic Solutions business (completed Feb 9, 2026) as discontinued operations. The recast New BD continuing operations show Q1 fiscal 2026 revenue of $4.486B, up 3.5% reported and 2.5% on a currency-neutral basis versus the prior-year recast period, with adjusted diluted EPS from continuing operations of $2.50, down from $2.78 in the year-ago period.
Key Financial Metrics
Key Facts
- BD completed the spin-off of its Biosciences and Diagnostic Solutions business and combination with Waters Corporation on February 9, 2026.
- Recast New BD continuing operations Q1 fiscal 2026 revenue: $4.486B, up 3.5% reported and 2.5% FXN vs. $4.333B in the prior-year recast period.
- Recast New BD continuing operations adjusted diluted EPS (non-GAAP) for Q1 fiscal 2026: $2.50, down from $2.78 in the prior-year recast period.
- GAAP diluted EPS from continuing operations for recast New BD: $1.09 vs. $0.50 in the prior-year recast period.
- Full-year fiscal 2026 New BD guidance maintained: adjusted diluted EPS of $12.35 to $12.65 and low single-digit revenue growth (FXN).
Financial Impact
Recast Q1 FY2026 New BD revenue $4.486B (+3.5% reported); adjusted diluted EPS $2.50 (-10.1% vs $2.78 prior year). FY2026 guidance unchanged: adjusted EPS $12.35-$12.65.
Risk Factors
- Adjusted diluted EPS from continuing operations declined 10.1% YoY in the recast Q1 period.
- Life Sciences segment (now discontinued) contributed $766M in revenue in Q1 FY2026; its removal reduces the top line and may alter growth comparisons going forward.
- The recast financials are unaudited and may be subject to revision.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-023185 |
| Document: bdx-20260402.htm | 0001628280-26-023185 |
| Document: 0001628280-26-023185-index-headers.html | 0001628280-26-023185 |
| Document: 0001628280-26-023185-index.html | 0001628280-26-023185 |
| Document: 0001628280-26-023185.txt | 0001628280-26-023185 |
| 8-K Data (Synthetic) | 0001628280-26-023185 |
Track record
17 reports on BDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20265d ago 144 Neutral 2/10 Entry $214.52 Now $216.47 +0.91% settles Nov 18
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $211.88 to $218.03 Now $216.47 +2.17% ▲ +2.90% +0.31% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $211.88 to $218.03 Now $216.47 +2.17% ▲ +2.90% +0.31% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $213.55 to $215.71 Now $216.47 +1.37% ▲ +1.01% −2.28% vs SPY
- Nov 5, 202611d ago Press Release Neutral 3/10 Entry $213.55 to $215.71 Now $216.47 +1.37% ▲ +1.01% −2.28% vs SPY
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $209.19 to $214.52 Now $216.47 +3.48% ▲ +2.55% +3.46% vs SPY
- Oct 26, 202621d ago 144 Neutral 2/10 Entry $195.03 to $198.17 Now $216.47 +10.99% ▲ +1.61% +3.60% vs SPY
- Oct 6, 20265w ago Press Release Neutral 2/10 Entry $180.30 to $187.37 Now $216.47 +20.06% ▲ +3.92% +4.06% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $182.09 to $190.74 Now $216.47 +18.88% ▲ +4.75% +5.94% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $153.16 to $168.40 Now $216.47 +41.34% ▲ +9.95% +12.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers